Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976723 · ClinicalTrials.gov registry record · Phase 4
Nerivio Efficacy by Time of Treatment Onset
A Phase 4 study, sponsored by Theranica.
- Completed
- Registry status
- Phase 4
- Development phase
- 55,261
- Enrollment target
NCT06976723: Completed Phase 4 study, sponsored by Theranica.
NCT06976723 is a Phase 4 study that has completed, run by Theranica. The registered enrollment target is 55,261 participants, above the 512-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10693% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06976723, a Phase 4 study, has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55,261 participants
- Enrollment target
Study Summary
This is a Post-marketing study investigating the impact of treatment time onset with Nerivio on the efficacy of Remote Electrical Neuromodulation (REN) for the acute treatment of migraine. Efficacy will be evaluated as a change in headache pain severity and functional disability from baseline to 2 hours post-treatment in at least 50% of the treatments, based on the treatment start time from the beginning of the migraine attack.
Primary Outcome
Proportion of treatments in which there was a reduction in headache intensity from moderate or severe headache at baseline to mild or no pain 2 hours post-treatment.
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55,261 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2025-06-15 |
| Phase | Phase 4 |
What the finished NCT06976723 record still lists
NCT06976723 is an interventional study that assigns participants to a tested intervention. Its 55,261 participants enrollment target places it among the larger protocols in the corpus, above the 512-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10693% higher).
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT06976723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06976723 about?
NCT06976723 is a clinical study titled "Nerivio Efficacy by Time of Treatment Onset". This is a Post-marketing study investigating the impact of treatment time onset with Nerivio on the efficacy of Remote Electrical Neuromodulation (REN) for the acute treatment of migraine. Efficacy will be evaluated as a change in headache pain severity and functional disability from baseline to 2 ...
What is the current status of trial NCT06976723?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55,261 participants. The study started on 2025-05-07. Estimated completion is 2025-06-15.
What interventions are being tested in trial NCT06976723?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT06976723?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06976723's enrollment target sits among peer trials
55,261 4th of 2000 higher than 1,997 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07224243 · 54,000 participants · NA
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT06355934 · 52,121 participants
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- NCT00785525 · 60,000 participants · Phase 3
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI